DrugPatentWatch Database Preview
« Back to Dashboard
Summary for Patent: 8,067,472
|Title:||Methods of treating Hodgkin's and non-Hodgkin's lymphoma|
|Abstract:||The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.|
|Inventor(s):||Richon; Victoria M. (Rye, NY), Chiao; Judy H. (Berkeley Heights, NJ), Kelly; William Kevin (Scotch Plains, NJ), Miller; Thomas A. (Brookline, MA)|
|Assignee:||Merck HDAC Research, LLC (Boston, MA) Sloan-Kettering Institute for Cancer Research (New York, NY)|
1. A method of treating non-Hodgkin's lymphoma in a patient, comprising orally administering to said patient a single dose of 400 mg daily of suberoylanilide hydroxamic acid
(SAHA) represented by the following structure: ##STR00062## or a pharmaceutically acceptable salt or hydrate thereof.
2. The method of claim 1, wherein suberoylanilide hydroxamic acid (SAHA) is administered.
3. A method of treating Hodgkin's lymphoma in a patient, comprising orally administering to said patient 200 mg twice daily of suberoylanilide hydroxamic acid (SAHA) represented by the following structure: ##STR00063## or a pharmaceutically acceptable salt or hydrate thereof.
4. The method of claim 3, wherein suberoylanilide hydroxamic acid (SAHA) is administered.
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally: